Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

News

Scrip World Pharmaceutical News was established in 1972 and - since that time - has continued to serve as the leading news and information source for the world's pharmaceutical and biotech industries. Scrip's team of more than 20 writers, analysts and editors provide the latest news, features and commentary from around the globe.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:
    ThromboGenics
    Dr. Patrik De Haes, CEO
    Tel: +32-16-75-13-10
    patrik.dehaes@thrombogenics.com

    Chris Buyse, CFO
    Tel: +32-16-75-13-10
    chris.buyse@thrombogenics.com

    Citigate Dewe Rogerson
    Amber Bielecka/ David Dible/ Nina Enegren
    Tel: +44-207-638-95-71
    amber.bielecka@citigatedr.co.uk



'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... The wet form ... of special anti-vascular endothelial growth factor agents given by injection into the eye. ... have a scientific protocol for the many millions diagnosed with it. AMD usually ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/bvxxkf/cytogenetics ) has announced the addition ... - Technologies, Markets and Companies" to ... cytogenetics includes several technologies besides fluorescence in ... and multicolor FISH. Molecular cytogenetics includes application ...
(Date:9/2/2015)... 2, 2015  Neurotech Pharmaceuticals, Inc., announced today ... multicenter Phase 2 clinical trial of NT-503 Encapsulated ... recurrent subfoveal choroidal neovascularization secondary to age related ... vascular endothelial growth factor (VEGF) receptor protein continuously ... "This landmark proof-of-concept study will evaluate NT-503 ECT ...
(Date:9/2/2015)... , Sept. 2, 2015 Veracyte, Inc. (NASDAQ: ... Anderson , president and chief executive officer, will present ... September 16, 2015 at 10:30 a.m. ET in ... The live audio webcast and subsequent replay may be ... will be available shortly after conclusion of the presentation ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Veracyte to Present at Morgan Stanley Global Healthcare Conference 2
... have developed a method for culturing mammalian neurons in chambers ... extends the lifespan of the neurons at very low densities, ... growth and behavior of individual brain cells. , The technique ... Society of Chemistry Lab on a Chip. , This ...
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) will be presenting ... at 2:30 p.m. ET in New York, at,the Thomas ... a.m. ET in Boston and at the Bear Stearns ... ET in New York. Daniel M. Bradbury,President and Chief ...
... New company offers innovative casting, splinting and ... 31 Enova Medical Technologies,Inc. of St. ... of Aspen,Colo., are pleased to announce the ... that will develop and commercialize innovative orthopedic,support ...
Cached Biology Technology:Microfluidic chambers advance the science of growing neurons 2Microfluidic chambers advance the science of growing neurons 3Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference 2Enova Medical Launches Exos Corporation 2
(Date:8/19/2015)... 2015  VOXX International Corporation (Nasdaq: VOXX ... a Definitive Agreement to purchase the assets, inclusive ... leader EyeLock through an acquiring entity.  Upon consummation ... interest in the acquiring entity. The closing of ... diligence.  Expanding on its existing supply chain and ...
(Date:8/18/2015)... Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) ... Biometric Authentication & Identification Market: Focus On Modality, ... report to their offering. ... is expected to grow at an estimated CAGR ... over $25 billion (approximately) by 2020 as per ...
(Date:8/12/2015)... Minn. , Aug. 12, 2015   MedNet ... supports the entire spectrum of clinical research, is proud ... , the company,s comprehensive SaaS-based eClinical technology platform, has ... during the first two quarters of 2015.   Q2 ... second largest quarters measured by contract value sold in ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
... Biofuels based on ethanol, vegetable oil and other renewable ... a way to reduce fossil fuel dependence and limit ... a biologist at the University of Washington, Bothell, shows ... might have exactly the opposite impacts than intended. The ...
... Clouds have typically posed a problem to scientists using ... where humans live and breathe, because they block the ... Earth,s surface. It turns out, however, that these "obstructions" ... characteristics actually serve a valuable role in Earth,s climate. ...
... RELEASE, 26 May 2008] Scientists at the Swedish medical ... that is much cheaper than those currently in use ... make it possible to map disease genes in large ... for new treatments for a wide variety of diseases. ...
Cached Biology News:Some biofuels might do more harm than good to the environment, study finds 2Some biofuels might do more harm than good to the environment, study finds 3Satellites illuminate pollution's influence on clouds 2Satellites illuminate pollution's influence on clouds 3New cheaper method for mapping disease genes 2
... rapid analytical to medium scale affinity purification ... vectors. Sufficient reagents are provided for purification ... under native or denaturing conditions. Crude samples ... retains STag fusion proteins. After unbound proteins ...
... AAIPharmas Biotech Solutions Group combines deep experience, ... special qualities of collaborative team chemistry. This ... concept to approval and beyond.,With AAIBiotech, you ... But you get more than that: its ...
S-100 alpha/beta chain (8B10)...
... number is a new product number, ... number. If showing no availability yet, ... number (Z71,487-9) or contact customer service ... neck 100 mm, No. of sidearm ...
Biology Products: